All posts by imreal

Predicting the Next Emerging Disease Requiring In Vitro Diagnostics (IVDs)


This is a high competitor-involvement IVD market. That’s because although most markets today are small, outside of TB and malaria, the opportunity is great for finding the most effective test for Disease X.

Kalorama estimates a $3.7 billion market for emerging diseases. This market is expected to grow to $4.9 billion in 2026. This is based on its recent report “Emerging Infectious Disease Market Trends, 2022.”

In 2015 the World Health Organization held a workshop on prioritization of pathogens “for accelerated R&D for severe emerging diseases with potential to generate a public health emergency, and for which no, or insufficient, preventive and curative solutions exist.” The list was updated in 2018 and again in 2021. Among these are Ebola, Zika, MERS, Nipah Lassa Fever and others.

“This is a high competitor-involvement IVD market. That’s because although most markets today are small, outside of TB and malaria, the opportunity is great for finding the most effective test for Disease X,” says Bruce Carlson, publisher for Kalorama Information.

A particular concern is mosquito borne diseases, because of the speed by which they can spread and recent trends of ‘island-hopping’ diseases into the United States via the Caribbean. For many mosquito-borne illnesses, there is no vaccine and little in the way of treatment as the infections are viral. Thus preventing the illness is key. Malaria, Chikungunya, Yellow Fever, Dengue, West Nile Virus and Zika are among these diseases.

Disease prevention is dependent on local governments and even homeowners in some cases. Local mosquito control departments ascertain the numbers and types of mosquitoes in an area and the infections they may be spreading. Professionals share prevention information with the public and use multiple methods at the same time to kill mosquito larvae and adult mosquitoes. Professionals from local government departments or mosquito control districts develop mosquito control plans, perform tasks to control mosquito larvae and adult mosquitoes, and evaluate the effectiveness of actions taken. Methods can include eliminating mosquito larval habitats, applying larvicides to kill mosquito larvae, or spraying insecticides from trucks or aircraft to kill adult mosquitoes.

Mosquitos have natural predators that collectively can exert some influence on reducing mosquito populations. However, with a very few exceptions, predators generally have little effect on reducing the mosquito population over a large area. Predators of mosquitos include: Bats , Birds, Goldfish, guppies, bass, bluegill and catfish prey on mosquito larvae. Frogs and Tadpoles, Turtles, Dragonflies, Damselflies and Spiders.

Non mosquito-spread diseases of concern include: Tuberculosis, Chagas, Lyme Disease Marburg virus, Rift Valley Fever, Ebola, Ross River Virus, CCHF, Nipah and Lassa Fever. Scores more are detailed in the report.

This is a company with high competitor involvement. Large IVD concerns are involved in developing and marketing tests for emerging diseases. So are smaller companies with innovative tests. Companies with products in this market include: Roche, Abbott, OraSure, Cepheid, Bruker, Thermo Fisher, Siemens Healthineers, ELITechGroup, Arkray Healthcare, Zeus Scientific , Ortho Clinical Diagnostics, Alpha Diagnostics, Altona Diagnostics, Savyon Diagnostics, Oxford Immunotec, Avioq, Biocartis, Biomeme, Qiagen, Fujirebio, Hologic, InBios, Becton Dickinson, BGI, bioMérieux, SD Biosensor NovaTec , Seegene, Vela Diagnostics , Trinity Biotech and many other companies.

Share article on social media or email:

Empathia, Inc. Announces New Partnership With Togetherall


Empathia, Inc.

Empathia, Inc.

Empathia, Inc. partners with Togetherall to offer its leading peer-to-peer virtual support platform to members of its LifeMatters Employee Assistance Program, Black Swan Solutions Crisis Management Service and StudentLife Student Support Program.

Empathia, Inc. has partnered with Togetherall to increase the mental health offerings available for its members. Togetherall is a leading virtual platform providing safe, clinician-monitored communities for peers to share mental health struggles while receiving and offering support. Championing security, anonymity, and clinical oversight, Togetherall’s technology is a valuable addition for many organizations.

“Empathia is constantly looking for new ways to engage those we serve, and to offer innovative ways to provide support,” said Empathia’s Chief Growth Officer, Brian Summers. “We are excited about our relationship with Togetherall, as they expand our services and align with our culture of, and commitment to, clinical wellbeing. Through Togetherall, we’re able to provide a safe online community that’s accessible 24/7.”

Togetherall’s peer-to-peer model supports over 20 million people worldwide across a variety of employer, health, union, association and student markets. With Togetherall’s capabilities, organizations can engage populations that have been traditionally underserved, create safe discussion spaces within industries where mental health may be stigmatized, and provide access to 24/7 support moderated by licensed clinicians. From small communities to large — such as student, healthcare, BIPOC and nationwide populations — individuals can connect to others with similar situations and struggles to find comfort and support. Togetherall also offers additional resources, courses, goal-setting tools and self-assessments that help individuals monitor and develop proactive mental health skills. With Empathia’s dedicated 24/7 clinical call center and digital services, members can seamlessly connect to other support resources when needed.

“Togetherall is passionate about the role that peer-to-peer support plays in mental health, ensuring that individuals and whole populations can connect safely with the resource that’s right for them,” said Togetherall President Matthew McEvoy. “Every day we see the power of people helping each other by sharing their thoughts, feelings, stories and encouragement. We are looking forward to extending our 24/7 service to Empathia and their broad portfolio of clients, integrating into their core offerings to provide appropriate pathways and a seamless member experience.”

Ben Locke, Ph.D., Chief Clinical Officer at Togetherall added, “Traditional treatments will always play a critical role in supporting people struggling with mental health concerns, but we must also realize that these services are simply not designed to scale and therefore cannot meet the demand alone. And, those who are most in need and at risk often suffer alone, afraid or unable to navigate traditional treatment systems. Togetherall’s model of peer support is accessible 24/7 and is always moderated by licensed clinicians, both to ensure a safe, supportive space and to provide members with more intensive support or safeguarding when needed. The clinical and technological integration with Empathia’s 24/7 clinical call center is an important part of our partnership as we put the member first, whatever their level of need.”

Empathia’s clients may now add Togetherall as a valuable resource to their existing plan. Together, Empathia and Togetherall are committed to expanding the reach of mental health services and ensuring individuals have access to reliable, convenient support.

About Togetherall

Togetherall is the leading peer-to-peer online mental health service that provides millions of people throughout North America and Europe with access to a safe community moderated by licensed clinicians, 24 hours a day, 365 days a year. Harnessing the protective and therapeutic effects of connectedness and healthy social networks in its unique community where people share with and support each other, Togetherall has supported over 350,000 members with their mental health in partnership with organizations in the corporate, education, health and charity sectors as well as the Armed Forces. A social impact organization guided by three core principles of inclusive access, measurable impact and financial self-sufficiency and stainability. Visit our website at: togetherall.com.

About Empathia, Inc.

Empathia is an industry-leading, full-service global provider of Employee Assistance Programs (EAP), Student & Family Assistance Programs (SFAP) and Crisis Management Services. For over 35 years, Empathia has delivered reliable, quality-driven services to organizations ranging from Fortune 500 companies to small, locally-owned businesses. For more information, visit empathia.com.

Share article on social media or email:

Biopharma Excellence Launches Groundbreaking ‘Science Huddle’ Series With First Panel Debate on Statistical Significance in a ‘Small Data’ World


Each Science Huddle will bring together some of the sharpest minds in their field to air the emerging issues and identify practical ways forward.

Biopharma Excellence has launched a groundbreaking new Science Huddle panel debate series, with a high-impact first session delving into Small data, big outcomes: strategies for achieving statistical significance when global patient populations are limited.

Confirmed participants include experts in the field:

· Daniel O’Connor, Deputy Director, Innovation Accelerator and Regulatory Science, MHRA

· Nick Sireau, CEO and Chair of Trustees for the AKU Society

· Rachelle Jacques, President and CEO, Akari Therapeutics

Dr. Christian K. Schneider, Head of Biopharma Excellence and a world expert in adapting existing regulatory frameworks for biopharmaceuticals, will moderate the event.

The Science Huddle, Sparked by Biopharma Excellence, is a groundbreaking new series of quarterly thought leadership panel discussions, featuring key stakeholders from across the life sciences ecosystem, focusing on the complex challenges in the race to bring critical, cutting-edge treatments to patients.

The powerful forum will bring together senior representatives such as regulators, investors, product developers, scientists and patient advocacy groups, for frank exchanges that give rise to actionable ideas.

Commenting on the launch of the Science Huddle, and the announcement of the first panel, Head of Biopharma Excellence, Dr. Christian K. Schneider, said: “Advanced/Cell & Gene Therapies are a huge and growing focus for life science product developers, investors, regulators, patients with rare conditions and the clinicians treating them. Yet, despite huge efforts to expedite new innovation, some significant and complex challenges remain.

“It has never been more important for stakeholders from across the life sciences ecosystem to join forces and find answers to the issues threatening to delay market access to these critical treatments.

From achieving statistical significance with small clinical trial populations, to the criticality of an integrated product development strategy, to tackling the risks of empty capsids in trials of gene therapies, each Science Huddle will bring together some of the sharpest minds in their field to air the emerging issues and identify practical ways forward.”

From medical science to data science, product commercialisation and reimbursement, the Science Huddle panel series will examine challenges and devise viable and sustainable solutions across the full lifecycle of Advanced/Cell & Gene Therapy development and delivery.

Future Science Huddles, due to take place quarterly, will address:


  • Proposed approaches to the practical problem and associated risks of empty capsids in gene therapy trials.
  • The fallout of poor global product development planning, and the advantages of starting a dialogue with regulators much earlier in the cycle.
  • The difference a more aggressive strategy can make in biosimilar delivery and market success.

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence, under the PharmaLex brand. Established as a distinct entity in October 2021, the service line combines 35+ years of empirical experience and respected regulator relationships. Its global team of 70+ scientific, regulatory and commercial professionals offer strategic product development and proactive regulatory services geared specifically to developers of advanced therapy medicinal products (ATMPs).

Biopharma Excellence’s growing prominence comes as the maturation of the biopharma industry accelerates, giving commercial form to important new innovation in fields including cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

The first Science Huddle is on November 2nd at 3-4 CET. Register to book your FREE place, here

About Biopharma Excellence

Biopharma Excellence partners with biopharmaceutical companies on their journeys toward the development and delivery of scientific advances and product breakthroughs. Its worldwide team of experts comprises multidisciplinary scientists; specialists in cell and gene therapies, vaccines, monoclonal antibodies and process development; clinicians; and former regulators. Biopharma Excellence has a proven track record in developing solutions to the scientific, regulatory and commercialization challenges that are unique to biopharmaceutical companies. These global solutions are grounded in major regulatory markets across Europe, the United States and Australia. More at http://www.biopharma-excellence.com.

For further information, please contact:

Carina Birt, PR for Biopharma Excellence

carina@sarumpr.com

+44 7970 006624

Share article on social media or email:

Durie Tangri to Join Morrison Foerster


News Image

Leading global law firm Morrison Foerster and premier litigation boutique Durie Tangri today announced that Durie Tangri will join Morrison Foerster effective January 1, 2023. Durie Tangri’s lawyers will further strengthen Morrison Foerster’s intellectual property (IP), complex civil litigation, and trial capabilities and its leading position at the cutting-edge of technology and life sciences. Thirty-six Durie Tangri lawyers are anticipated to join Morrison Foerster, including 12 partners.

Durie Tangri has one of the nation’s premier trial practices and represents clients in diverse areas of complex litigation, including IP (patent, trademark, and copyright), professional liability, privacy, white-collar crime and investigations, contract and commercial matters, and class actions, as well as appellate matters. Recent notable representations include several post-COVID jury trial victories in 2021 and early 2022, including: a defense verdict for Activision Blizzard in a copyright case over its blockbuster Call of Duty Black Ops 4 videogame; a defense verdict for Redbubble in a copyright and trademark infringement case brought by Atari; and a defense verdict in a patent case for Aptiv over USB technology.

Durie Tangri was co-founded in San Francisco in 2009 by Daralyn Durie, Ragesh K. Tangri, Mark A. Lemley, and Joseph (Joe) C. Gratz, among others. In just over a decade, Durie Tangri has seen significant growth and considerably expanded its client base and capabilities, opening a second office in Los Angeles in 2018. The firm was named IP Boutique of the Year by Managing IP and Intellectual Property Firm of the Year by Benchmark Litigation in 2022. Its partners have also been widely recognized as preeminent practitioners in their fields. Founders Daralyn Durie, Ragesh K. Tangri, Mark A. Lemley, and Joe C. Gratz are ranked by Chambers, with Durie ranked among Band 1 in IP nationally; Tangri ranked among Band 1 in IP: Trademark, Copyright & Trade Secrets Litigation in California; Lemley ranked among Band 2 in IP: Patent Litigation in California; and Gratz ranked among Band 2 in IP: Trademark, Copyright & Trade Secrets Litigation nationally.

Durie Tangri has an equally impressive bench, representing the next generation of trial talent. Benchmark Litigation named Adam Brausa and Kira Davis Litigation Stars, with Davis also noted as a Patent Star by Managing IP. The Daily Journal named Tim Saulsbury and Eugene Novikov among California’s Top 40 Lawyers Under 40, and Benchmark Litigation recognized the pair on its 40 & Under Hotlist. LMG Lifesciences ranks Brausa and Davis for Patent Litigation nationally, and The American Lawyer shortlisted Novikov as a Young Lawyer of the Year Finalist.

“We are thrilled to welcome the Durie Tangri team to Morrison Foerster,” said Eric McCrath, chair of Morrison Foerster. “Their stellar IP, complex civil litigation, and trial law capabilities will add significant strength and talent to our ranks on the West Coast. Our shared commitment to serving clients on the forefront of technology and life sciences, while staying true to our values, in particular our commitment to diversity and inclusion, make this the perfect match for our firm.”

“Providing access to Morrison Foerster’s global platform will be transformational for our lawyers’ ability to grow their practices and is a natural next step in our evolution,” said Daralyn Durie. “Morrison Foerster’s deep roots in the Bay Area, continued tradition of leadership in the tech and life sciences sectors, coupled with its well-respected bench of IP lawyers, and premier litigation department all make MoFo the ideal fit for us. We look forward to carrying on its tradition of trial excellence.” Ragesh K. Tangri added: “We are proud of what we have built and achieved in the last several years at Durie Tangri. We look forward to bringing our next generation of diverse trial talent and shared values to the firm, and focusing on developing the best trial teams for clients across MoFo’s global platform and scale.”

Morrison Foerster is widely recognized as a litigation powerhouse and IP and patent leader. In the last five years, Morrison Foerster lawyers have litigated more than 300 patent disputes in the most active district courts in the U.S., including the Eastern and Western Districts of Texas, the District of Delaware, and the Northern and Central Districts of California. Further, the firm’s more than 115 patent attorneys and patent agent/scientific analysts offer clients around the world unrivaled industry and technical experience.

In 2019, Morrison Foerster opened an office in Boston, significantly strengthening its IP capabilities on the East Coast. Earlier this year, the firm opened an office in Austin with an initial focus on advising companies, including emerging growth companies, and investors in the technology, life sciences, and healthcare sectors, on IP litigation and transactional matters. As part of the opening, leading IP practitioners Brian C. Nash and Aaron G. Fountain joined the firm’s IP Litigation Group.

Share article on social media or email:

Dr. Lozada Shares Expertise as Invited Faculty at The Penn International Rhinoplasty Course


Dr. Lozada Shares Expertise

Dr. Lozada Shares Expertise as Invited Faculty at The Penn International Rhinoplasty Course

The Penn International Rhinoplasty Course brings together some of the best and brightest in rhinoplasty from around the world. I was honored to be an invited speaker to share my knowledge with my colleagues and learned a lot as well!

Dr. Kirk Lozada of Lozada Facial Plastic Surgery recently participated in the Penn International Rhinoplasty Course on September 9th, 2022, as an invited faculty member. This was an excellent opportunity for Dr. Lozada to share his expertise on liquid rhinoplasty, filler emergencies, and social media as it pertains to medical practices.

The Penn International Rhinoplasty Course brought together some of the top facial plastic surgeons in the country to cover valuable topics, including functional and aesthetic nasal surgery, safety in septorhinoplasty, and tips on the latest concepts and techniques in rhinoplasty procedures.

Dr. Lozada is one of Philadelphia’s leading facial plastic surgeons and rhinoplasty experts. He specializes in liquid rhinoplasty, which is a quick in-office procedure that can change the shape of the nose without surgery. He shared his techniques with the audience for safe and effective results.

Social media is always a hot topic at meetings, and Dr. Lozada is frequently requested to share his knowledge on the topic. Dr. Lozada discussed his use of platforms such as Instagram and Tiktok and how that fits into an overall marketing strategy to grow a business.

Dr. Lozada also lectured on filler complications and management. Dr. Lozada sees many patients in his office who have suboptimal results from filler. He is an expert in managing filler complications and giving patients a natural-looking outcome they are happy with.

The course was a resounding success with an excellent turnout of attendees, including general otorhinolaryngologists as well as medical professionals focusing their practice on rhinology and facial plastic surgery. Attendees were able to earn CME credit while engaging with distinguished faculty.

About Dr. Kirk Lozada

Born and raised in Honolulu, Hawaii, Dr. Kirkland N. Lozada is a second-generation Facial Plastic Surgeon and rhinoplasty expert. He is renowned for his new and innovative techniques that provide beautiful, balanced, and natural-looking results.

Dr. Lozada earned his Bachelor of Science in biology at the University of Pennsylvania and completed medical school at Jefferson Medical College. He completed his residency training in Otolaryngology-Head & Neck Surgery at the New York Eye & Ear Infirmary of Mount Sinai and returned to the University of Pennsylvania for his facial plastic surgery training.

Throughout his career, Dr. Lozada has worked with some of the top facial plastic surgeons in Philadelphia, New York, and New Jersey. He is currently a member of the American Academy of Facial Plastic & Reconstructive Surgery and is faculty for the Penn Facial Plastic Fellowship program.

Dr. Lozada has numerous publications in the field of facial plastic surgery. He is the editor of two international textbooks on rhinoplasty and non-surgical rejuvenation. He also lectures and frequently presents on topics relating to otolaryngology and facial plastic surgery.

By employing cutting-edge techniques performed by only a few surgeons in the country, Dr. Lozada is able to achieve safe and natural results. His specialties include rhinoplasty, facelifts, and eyelid (blepharoplasty) surgery. Dr. Lozada provides a personalized experience for each and every patient based on their unique needs and goals.

About the Penn International Rhinoplasty Course

The Penn International Rhinoplasty Course provides valuable information for practicing clinicians, scientists, residents with an interest in rhinology and rhinoplasty, and nursing staff who care for patients with nasal problems. Experts cover common conditions as well as difficult problems in rhinoplasty and facial surgery.

The comprehensive program includes discussion panels with distinguished faculty who speak on a wide range of topics. Material covered includes evaluation and analysis of the nose, basic and advanced nasal anatomy, treatment of surgical failures, prevention and management of rhinoplasty complications, and much more.

Attendees have the opportunity to learn from and engage with experts in the fields of rhinoplasty and facial plastic surgery. Lectures include audience participation and discussion. Attendees can also participate in a laboratory dissection session and earn CME credit.

Upon completion of the course, participants should be able to analyze the face and nose and consider aesthetic ideals, develop a rationale for surgical treatment of nasal deformity and nasal obstruction, assess deformities of the nasal valve and prescribe surgical corrections, and be aware of how to avoid complications in rhinoplasty.

About the Lozada Facial Plastic Surgery

Lozada Facial Plastic Surgery is Philadelphia’s premier rhinoplasty and facial plastic surgery practice. Headed by Dr. Kirk Lozada, the practice employs modern-day techniques to achieve beautiful, balanced results. Treatment options include surgical and non-surgical procedures.

Unbalanced facial features can be a source of insecurity. The experts at Lozada Facial Plastic Surgery have a deep understanding of facial proportions and the artistic interplay of shadows and light. Using cutting-edge technology and techniques, Dr. Kirk Lozada helps patients gain confidence and promote their natural beauty.

At Lozada Facial Plastic Surgery, personalized treatment plans are essential. Consultations are scheduled with sufficient time to fully develop a unique understanding of each patient’s needs and aesthetic goals. Each patient receives a comprehensive, individualized treatment plan that is effective and natural.

Surgical procedures include rhinoplasty, facial reconstructive surgery, eyelid surgery and much more. Non-surgical procedures include, but are not limited to, Botox, dermal fillers, Kybella, and Sculptra. Dr. Lozada will advise you on which procedure is right for you and give you detailed information about what the procedure involves.

If you’re interested in learning more about cutting-edge rhinoplasty procedures such as scarless rhinoplasty and revision rhinoplasty, as well as other aesthetic surgical and non-surgical procedures, contact Lozada Facial Plastic Surgery today.

Design for Leisure Launches Event Sauna Services and World-Class Sauna Aufguss Training for USA and UK Markets


Photo credit: Megan Blair

Experiential, communal social sauna-ing is gaining popularity the world over as more people seek back-to-basic wellness that simply feels good for mind, body and spirit.

Design for Leisure (DFL), award-winning hydrothermal spa and wellness specialists, today announced a new comprehensive Event Sauna Services program to better accommodate the growing demand for European-style communal, social sauna experiences in the US and UK. The program offers spas, urban bathhouses and wellness centers a turnkey solution for bringing their own signature Sauna Aufguss experience to life and an opportunity to create an entirely new revenue stream.

Event Saunas are specially-designed, large saunas that typically accommodate at least 10 people (the largest in the world hosts up to 300). In addition to housing more bodies than a typical sauna cabin, they also need to provide enough space for Sauna Masters to perform the “Art of Aufguss” or lead group classes, like meditation or breathwork.

“It’s crucial to purpose-design an Event Sauna from the ground up, but the payoff is significant,” says Don Genders DFL’s CEO. “Individual performances can be upsold, and, depending on capacity, facilities that maintain a 50-person daily occupancy, for example, can easily generate an additional $2,000/day with little additional operational costs.”

“Experiential, communal social sauna-ing is gaining popularity the world over as more people seek back-to-basic wellness that simply feels good for mind, body and spirit. Saunas provide a unique, device-free refuge from our manic world – a place to slow down, share space and enjoy the euphoric sensations that naturally come from thermal therapy. Sauna-ing with like-minded individuals enhances the power of this ancient practice,” said Genders, who also serves as the Chair of the Global Wellness Institute’s Hydrothermal Initiative.

DFL is the team behind the design and build of the first-ever Event Sauna in North America at Resorts World AWANA Spa & Wellness in Las Vegas. In addition, the company recruited Lasse Eriksen to head up Aufguss Training services for AWANA, a role he continues in as DFL expands its Event Saunas Services.

Eriksen, a well-respected figure in sauna bathing, serves as the Vice President of the Aufguss World Championships and President of the Norwegian Sauna Association, and has put together an award-winning team to deliver authentic Aufguss Training in partnership with DFL.

In addition to practical and theoretical Aufguss Training, DFL also provides management teams with a workshop for maximizing ROI. An ROI calculation for Event Saunas can be found here.

In fact, the company is so enthusiastic about the adoption of Event Saunas in the US and the UK that they are offering design services (up to a $10,000 value) to qualifying properties who are looking to build an Event Sauna that can accommodate a minimum of 10 people within the next 12 months.

Note: Don Genders will speak at the International Sauna Congress in Stuttgart, Germany later this month on the growing interest in sauna and thermal bathing in the USA.

About Design for Leisure: Designfor Leisure specializes in the design of award-winning hydrothermal spa and wellness environments. Headquartered in London and Austin, TX, the company has been creating high-end, turnkey wet spa areas for both luxury homes and commercial wellness projects for almost three decades. Clients include well-known hospitality and spa brands, such as Disney, Canyon Ranch, Caesars Palace, Four Seasons and Six Senses, as well as well-known architect groups, including Foster and Partners, Rogers Stirk Harbour + Partners, Bjark Ingels Group, Michael Graves and Thomas Heatherwick.

Share article on social media or email:

Successful Stories of Difficult Syntheses, Upcoming Webinar Hosted by Xtalks


Not only is the stapling moiety fundamental to mimicking biological activity but also the bridge size and its location and orientation within the bridge.

An increasing number of peptides are used in active pharmaceutical ingredients, cosmetics, diagnostics, and vaccines. Several are based on long sequences, cyclic structures, and multi-branched systems that require complex synthetic strategies to incorporate homodetic and heterodetic bridges, post-translational modifications, or constrained unnatural amino acids.

Therefore, peptide organic synthetic chemists have to overcome a variety of difficulties not only on a small scale but also during the scale-up. For example, side chain-to-side chain cyclizations represent a strategy for the enrichment of bioactive conformational ensembles. Structural rigidification reduces entropy and may lock molecules into receptor-binding conformations. Structural manipulations, therefore, contribute to the enhancement of target specificity, induce higher binding affinity and biological potency and often lead to lower metabolic susceptibility and more favorable pharmacokinetics.

In this webinar, the featured speaker will discuss the syntheses of biologically relevant cyclopeptides containing not only 1,4-disubstituted-[1,2,3]-triazolyl bridges but also interlocked dicarba bridges and 1,3-butadiyne constraints. This offers a powerful approach for generating stable helix mimetic structures or β-turn conformations. Not only is the stapling moiety fundamental to mimicking biological activity but also the bridge size and its location and orientation within the bridge.

Join this webinar to hear the speaker explore multiple parameters in technologies that improve the efficacy of solid-phase syntheses in complex peptides. The role of temperature, solvent volumes, coupling systems, and mixing modes (N2 bubbling and/or oscillation mixing) will be discussed, in addition, and how they can optimize protocols to develop the best conditions for the small-scale and mainly further upscaling of solid-phase synthesis.

Join Prof. Anna Maria Papini, University of Florence, Department of Chemistry “Ugo Schiff”, Interdepartmental Research Unit of Peptide and Protein Chemistry and Biology, for the live webinar on Friday, October 28, 2022, at 10 am EDT (3 pm BST/UK).

For more information, or to register for this event, visit Obtaining Complex Peptides Thanks to Efficient Technologies is No Longer a Dream: Successful Stories of Difficult Syntheses.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food, and medical device community. Every year, thousands of industry practitioners (from life science, food, and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends, and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Redi.Health Executive Confirmed as Speaker for Leading Pharmaceutical Conference


News Image

As a leader in health management technology, patient empowerment is a fundamental benefit of our platform, and we continue to seek opportunities to connect with others in healthcare about best practices.

Today, Redi.Health, provider of the leading health management technology that puts patient support in your pocket, is announcing that Co-Founder and CEO Luke Buchanan will be speaking at the Access Insights Conference in Baltimore next week. The three-day conference, designed for commercial, operational, and financial teams at pharmaceutical manufacturers, will feature industry executive and practitioner panels, including strategic and tactical programs focused on driving patient access and therapy commercialization. Buchanan will participate in two panel discussions to share strategies for implementing total health management through digital platforms.

“Digital health and the resulting transformation of care is taking center stage in every aspect of healthcare, particularly in the pharmaceutical industry, so we welcome the opportunity to share our insights and collaborate with other experts on ways to help manufacturers continue to evolve,” said Buchanan. “As a leader in health management technology, patient empowerment is a fundamental benefit of our platform, and we continue to seek opportunities to connect with others in healthcare about best practices.”

WHAT:

Access Insights Conference: Co-hosted by Blue Fin Group, an IntegriChain Company, the three-day Access Insights Conference will cover a broad range of topics focused on market access and therapy commercialization across data strategy, payer, contracts and pricing, gross-to-net, trade/channel, and patient access.

WHEN:

Tuesday, October 18, 2022

Trends in Patient Adherence Program Optimization

11:25 AM-12:10 PM

The Patient as a Consumer: Meeting Evolving Expectations in Healthcare Accessibility

4:15 PM-5:00 PM

WHERE:

Marriott Baltimore Waterfront, Baltimore, MD

To register or for more information about the Access Insights Conference, click here.

Redi.Health combines health management technology and pharmaceutical manufacturer support into one platform to enable patients to manage their complete health with a single interface. The company has integrated a robust data algorithm that allows Redi.Health to simultaneously connect patients to support offered by healthcare stakeholders, while providing insights to those stakeholders to ensure the right support is getting to the right patient at the right time. For more information about Redi.Health’s groundbreaking approach, visit https://www.redi.health/.

About Redi.Health

Redi.Health empowers patients with chronic conditions to understand, manage and track their total health through digital support. Combining health management technology and pharmaceutical manufacturer support into one tool, Redi.Health provides a mobile platform that allows patients to manage everything from multiple medications and symptoms to diet and exercise. By delivering a pathway for pharmaceutical companies, providers, and patients to connect and engage, Redi.Health customizes the complete health journey to drive better health outcomes.

Share article on social media or email:

KEB F6 VFD and S6 Servo Drive Achieves PROFIsafe Certification


Image of KEB F6 VFD and S6 Servo Drive

KEB F6 and S6 Drives are PROFIsafe Certified

“The PROFIsafe communication in KEB drives speeds up the commissioning time, reduces wiring, requires a smaller footprint, and comes with cost savings for machine builders.”

KEB America, Inc., a subsidiary of KEB Automation and a provider of industrial automation solutions in North America, today announces its F6 VFD and S6 Servo Drive is PROFIsafe certified. The PROFIsafe certification by TÜV Rheinland ensures KEB drives deliver functional safety over the bus to industrial machinery requiring PROFINET communication.

Functional safety is an integral component of KEB drives. The F6 VFD and S6 Servo Drive come standard with SIL3 Safe Torque Off (STO) and Safe Brake Control (SBC). Extra safety functionality such as Failsafe over EtherCAT (FSoE), SS1, SS2, SOS, SLS, SLP, SLI, SDI, and SSM is available.

“The certified PROFIsafe communication in our drives is a huge win for machine builders,” said Jonathan Bullick, sales manager at KEB America. “It speeds up the commissioning time, reduces wiring, requires a smaller footprint, and comes with cost savings.”

KEB’s COMBIVIS 6 commissioning and diagnostic software supports the F6 and S6 drive controllers to deliver exceptional speed and position control. These drives operate induction and AC permanent magnet servo motors with speeds up to 45,000 rpm. They feature flexible heatsinks, a dual-channel encoder card, power ranges from 0.75 kW to 450 kW, and internal positioning capability for motion control applications.

Visit KEB America’s website for more information and video demonstrations on its motion control and industrial automation solutions suite.

About KEB America, Inc.

KEB America, Inc. is a North American manufacturer of industrial automation products for applications in the elevator, medical, packaging, and plastics industries. KEB America manufactures, assembles, and supports its suite of German-engineered controls, drives, motors, brakes, and clutches at its ISO 9001:2015 certified 150,000 sq. ft. facility in Shakopee, Minnesota. For more information, please visit http://www.kebamerica.com.

KEB America is a wholly owned subsidiary of KEB Automation KG, a global provider of complete automation system solutions headquartered in Barntrup, Germany. KEB Automation KG has four global production sites, ten subsidiaries, 30 sales and service centers, and 1,500+ employees worldwide.

Share article on social media or email:

eMazzanti Technologies Offers Cyber Security Awareness Kit and Helpful Security Resources


Cyber Security Awareness Month

We expertly ensure all your security software is comprehensive and up to date, your emails protected, and your data encrypted while monitoring your network round the clock for suspicious activity.

eMazzanti Technologies, a NYC area business cyber security consultant, is offering a free Cyber Security Awareness Kit, designed to be delivered to interested parties in bitesize chunks over four weeks. The helpful kit forms the centerpiece of the company’s October Cyber Security Awareness Month observance.

eMazzanti will be updating the resources and highlighting services organizations need each week, covering everything from multi-factor authentication to software updates, and showing users how easy it is to improve their security posture.

The kit is available for free download to all interested parties on eMazzanti’s Cyber Security Awareness Month website.

“We expertly ensure all your security software is comprehensive and up to date, your emails protected, and your data encrypted while monitoring your network round the clock for suspicious activity,” stated Jennifer Mazzanti, CEO, eMazzanti Technologies. “We have the technology, people, and processes to deliver cost-effective premium cyber security solutions that scale as your business evolves.”

Additional Cyber Security Awareness Month Resources

eMazzanti’s Cyber Security Awareness Month website also includes numerous links to helpful business cyber security resources, including information about eCare Network Management services, multi-factor authentication, managing passwords, phishing awareness training, and software updates.

Visitors to the informative site may also find introductions to helpful cyber security eBooks, workshops, and videos, as well as additional offers for cyber security assessments, preliminary dark web monitoring, and email vulnerability testing.

Access Free Cyber Security Month Resources >>

Cybersecurity Awareness Month 2022

Since 2004, the President of the United States and Congress have declared October to be Cybersecurity Awareness Month, helping individuals protect themselves online as threats to technology and confidential data become more commonplace. The Cybersecurity and Infrastructure Security Agency (CISA) and the National Cybersecurity Alliance (NCA) lead a collaborative effort between government and industry to raise cybersecurity awareness nationally and internationally.

Partner with Cybersecurity Experts

For 21 years, eMazzanti Technologies has helped business leaders navigate the cyber security landscape to protect customer information and business assets. With an evolving threat landscape for business IT, eMazzanti encourages firms to update their cyber security strategies to be prepared.

Have you read?

Microsoft 365 Security Features Protect Business Data from Evolving Threats

Cyber Security for Business is Critical, Regardless of Business Size

ABOUT THE CISA CYBERSECURITY AWARENESS PROGRAM

The CISA Cybersecurity Awareness Program is a national public awareness effort that increases the understanding of cyber threats and empowers the American public to be safer and more secure online. It encourages Americans to view Internet safety as a shared responsibility–at home, in the workplace, and in our communities.

The CISA Cybersecurity Awareness Program is part of an unprecedented effort among federal and state governments, industry, and non-profit organizations to promote safe online behavior and practices. It is a unique public-private partnership, implemented in coordination with the National Cyber Security Alliance.

About eMazzanti Technologies

eMazzanti’s team of trained, certified IT experts rapidly deliver increased revenue growth, data security and productivity for clients ranging from law firms to high-end global retailers, providing advanced digital marketing services, cloud and mobile solutions, multi-site implementations, 24×7 outsourced network management, remote monitoring, and support.

eMazzanti has made the Inc. 5000 list 9X, is a 4X Microsoft Partner of the Year, the #1 ranked NYC area MSP and NJ Business of the Year! Contact: 1-866-362-9926, info@emazzanti.net or http://www.emazzanti.net Twitter: @emazzanti Facebook: Facebook.com/emazzantitechnologies.

Share article on social media or email: